Category Archives: Top Market News

Chardan Capital Reiterates Their Buy Rating on Moderna (MRNA)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Moderna (MRNA – Research Report), with a price target of $95.00. The company’s shares closed last Tuesday at $68.97. According to TipRanks.com, Livshits is a

L3Harris Technologies (LHX) Received its Third Buy in a Row

After Credit Suisse and Jefferies gave L3Harris Technologies (NYSE: LHX) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Gautam Khanna maintained a Buy rating on L3Harris Technologies today and set a

Prevail Therapeutics (PRVL) Gets a Buy Rating from Oppenheimer

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Prevail Therapeutics (PRVL – Research Report), with a price target of $25.00. The company’s shares closed last Tuesday at $13.55. According to TipRanks.com, Olson ‘s ranking

Alpine Immune Sciences (ALPN) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN – Research Report) yesterday and set a price target of $19.00. The company’s shares closed last Tuesday at $10.19. According to TipRanks.com, Breidenbach is a 5-star analyst

Motus Gi Holdings (MOTS) Receives a Buy from Oppenheimer

In a report released yesterday, Steven Lichtman from Oppenheimer maintained a Buy rating on Motus Gi Holdings (MOTS – Research Report), with a price target of $2.50. The company’s shares closed last Tuesday at $1.19. According to TipRanks.com, Lichtman is

Oppenheimer Sticks to Their Hold Rating for Sunesis Pharma (SNSS)

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sunesis Pharma (SNSS – Research Report) yesterday. The company’s shares closed last Tuesday at $0.33, close to its 52-week low of $0.20. According to TipRanks.com, Singh is a 5-star analyst with